Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies
Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
Publication date Nov 2017
Publisher Current Partnering
Number of pages 1,600+ (including appendices)
Report edition 2
Product code CP2053
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report.

 

This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology, device and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2010 to 2017.

 

The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.

 

A supply or manufacturing agreement is normally between a product manufacturer and product owner in which an owner outsources the manufacture and supply of its product(s) to the service company in a defined territory.

 

Manufacturing and supply agreements provide a popular method of maximizing the value of a product launched into a market. The deals allow the product marketer to focus on its sales and marketing efforts whilst relying on a third party to manufacture and supply product on demand, enabling rapid response to market demands. It also ensures that the marketer does not need to invest in costly infrastructure and expertise ahead of knowing whether the product will be successful or sustainable.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of over 2,500 manufacturing and supply deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of manufacturing and supply deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply deal making as well as a discussion on the merits of the type of deal.

 

Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.

 

Chapter 5 provides a review of the leading manufacturing and supply deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 6 provides a review of the top 50 most active biopharma companies in manufacturing and supply. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 7 provides a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2010 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply deal making since 2010.

 

In addition, a comprehensive appendix is provided organized by manufacturing and supply company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply partnering in the research, development and commercialization of technologies and products.  

 

Key benefits

 

Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:

 

  • In-depth understanding of manufacturing and supply deal trends since 2010
  • Analysis of the structure of manufacturing and supply agreements with numerous real life case studies
  • Comprehensive access to over 2,500 actual manufacturing and supply deals entered into by the world’s biopharma companies
  • Detailed access to actual manufacturing and supply deals entered into by the leading fifty bigpharma companies
  • Comprehensive access to all manufacturing and supply deals entered since 2010
  • Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 is intended to provide the reader with an in-depth understanding of the manufacturing and supply trends and structure of deals entered into by pharma, biotech, device and diagnostics companies worldwide.

 

Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 includes:

 

  • Trends in manufacturing and supply dealmaking in the biopharma industry since 2010
  • Analysis of manufacturing and supply deal structure
  • Case studies of real-life manufacturing and supply deals
  • Access to over 2,500 manufacturing and supply deal records covering pharma, biotech, devices and diagnostics since 2010
  • The leading manufacturing and supply deals by value since 2010
  • Most active manufacturing and supply dealmakers since 2010
  • The leading manufacturing and supply partnering resources

 

In Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available. 

 

The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to available records for over 2,500 maufacturing and supply deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides the reader with the following key benefits:

 

  • In-depth understanding of manufacturing and supply partnering deal trends since 2010
  • Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
  • Identify leading manufacturing and supply deals by value since 2010
  • Identify the most active manufacturing and supply dealmakers since 2010
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of  manufacturing and supply deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 2,500 manufacturing and supply deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual manufacturing and supply contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in manufacturing and supply deal making

 

2.1. Introduction

2.2. Difference between manufacturing and supply deals

2.3. Trends in manufacturing and supply deals since 2010

2.3.1. Manufacturing and supply deal making by year since 2010

2.3.2. Manufacturing and supply deal making by phase of development since 2010

2.3.3. Manufacturing and supply deal making by industry sector since 2010

2.3.4. Manufacturing and supply deal making by therapy area since 2010

2.3.5. Manufacturing and supply deal making by technology type since 2010

2.3.6. Manufacturing and supply deal making by most active company since 2010

2.3.7. When supply can be useful

2.4. Attributes of pure manufacturing and supply deals

2.5. Attributes of manufacturing and supply in multi-component deals

2.6. Reasons for including manufacturing and supply options in a multi-component deal

2.7. The future of manufacture and supply as part of multicomponent deals

 

Chapter 3 – Overview of manufacturing and supply deal structure

 

3.1. Introduction

3.2. Pure versus multi-component manufacturing deals

3.3. Pure manufacturing agreement structure

3.3.1. Example manufacturing agreements

3.3.1.a. Case study 1: Amyris Brazil – Biomin Nutricao Animal Do Brasil

3.3.1.b. Case study 2: Patheon – Orexigen Therapeutics

3.4. Manufacturing rights as part of a wider alliance agreement

3.4.1. Example multicomponent manufacturing clauses

3.4.1.a. Case study 3: Agenus Bio – NewVac

3.4.1.b. Case study 4: Elite Pharmaceuticals – Hi-Tech Pharmacal

 

Chapter 4 – Overview of supply deal structure

 

4.1. Introduction

4.2. Supply agreement structure

4.2.1. Example supply agreements

4.2.1.a. Case study 5: Omthera Pharmaceuticals – Catalent Pharma solutions

4.2.1.b. Case study 6: Endo Pharmaceuticals – Noramco

4.3. Supply rights as part of a wider alliance agreement

4.3.1. Example co-marketing right clauses

4.3.1.a. Case study 7: Auxilium Pharmaceuticals – Asahi Kasei

4.3.1.b. Case study 8: Durata Therapeutics - Hospira

 

Chapter 5 – Leading manufacturing and supply deals

 

5.1. Introduction

5.2. Top manufacturing and supply deals by value

 

Chapter 6 – Top 50 most active manufacturing and supply dealmakers

 

6.1. Introduction

6.2. Top 50 most active manufacturing and supply dealmakers

 

Chapter 7 – Manufacturing and supply deals contract directory since 2010

 

7.1. Introduction

7.2. Manufacturing and supply deals with contracts since 2010

 

Appendices

 

Appendix 1 – Manufacturing and supply deals by company A-Z

Appendix 2 – Manufacturing and supply deals by stage of development

Appendix 3 - Manufacturing and supply deals by deal type

Appendix 4 – Manufacturing and supply deals by therapy area

Appendix 5 – Manufacturing and supply deals by technology type

Appendix 6 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

TABLE OF FIGURES

 

Figure 1: Definition of manufacturing and supply

Figure 2: Types of manufacturing agreement

Figure 3: Trends in manufacturing and supply deal announcements since 2010

Figure 4: Manufacturing and supply deals signed at each phase of development since 2010

Figure 5: Manufacturing and supply deals by industry sector since 2010

Figure 6: Manufacturing and supply deals by therapy area since 2010

Figure 7: Manufacturing and supply deals by technology type since 2010

Figure 8: Top 50 most active manufacturing and supply dealmakers since 2010

Figure 9: Components of the manufacturing deal structure

Figure 10: Components of the supply deal structure

Figure 11: Top manufacturing and supply deals by value since 2010

Figure 12: Most active manufacturing and supply dealmakers since 2010

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2017 Wildwood Ventures Ltd.